Ferroptosis is a form of programmed cell death that occurs when excess iron causes lipid peroxides to build up on cell membranes.
By depriving ChRCC cells of cysteine, the team was able to induce ferroptosis, and they found evidence that this approach could be useful for treating ChRCC.
“Targeted therapies are urgently needed to treat renal chromophobe cancer,” said corresponding author Elizabeth P. Henske, MD, PhD, of the Division of Pulmonary and Critical Care Medicine at Brigham and Women’s Hospital.
“Through our research, we have uncovered strong evidence that ChRCC can be targeted for therapy by exploiting cellular hypersensitivity to ferroptosis. This represents a great deal of our knowledge as we consider treatments for patients with this rare disease An important breakthrough in understanding.”